Firm
The co-leaders of the firm’s new SEP practice group say the team will combine litigation and prosecution expertise to guide clients through cross-border challenges
Partners at three law firms explain why trade secrets cases are rising, and how litigation is giving clients a market advantage
In major recent developments, a team of partners broke away from Taylor Wessing to form their own firm, while Kilburn & Strode made a strategic UPC hire
Morgan Lewis adds three partners with technical depth, reinforcing the firm’s strategy to bridge legal and tech expertise in patent litigation
Sponsored
Sponsored
-
Sponsored by InspicosJakob Pade Frederiksen of Inspicos says a Unified Patent Court decision not to stay a revocation action while a parallel EPO opposition proceeding takes place provides another indication of the court’s fast pace
-
Sponsored by Tilleke & GibbinsSon Thai Hoang and Linh Thi Mai Nguyen of Tilleke & Gibbins highlight the strict stance taken by the Intellectual Property Office of Vietnam on assignments conflicting with trade names and join the calls for clearer guidance
-
Sponsored by Tilleke & GibbinsThe Central Intellectual Property and International Trade Court has confirmed that a design’s overall appearance should be considered when determining its eligibility for patent protection, report Nuttaphol Arammuang and Tanapong Pongburanakit of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law reports on a decision that should provide improved guidance in determining whether patents or approved drugs are eligible for a patent term extension in South Korea
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Shipra Alisha Philip of RNA, Technology and IP Attorneys analyse how a US ruling could affect digital libraries, e-book licensing, and public access to knowledge in India
-
Sponsored by Bird & BirdEmilia Zalewska and Andrzej Stelmachowski of Bird & Bird provide insights into two matters considered by the Unified Patent Court and a Polish court concerning the imminent infringement of patent rights in the pharmaceutical industry